ChromaDex Corporation (NASDAQ:CDXC) Q3 2024 Earnings Conference Call October 31, 2024 4:30 PM ET

Company Participants

Ben Shamsian - IR
Rob Fried - CEO
Ozan Pamir - CFO
Andrew Shao - SVP, Scientific & Regulatory Affairs
Wesley Yu - VP, Finance

Conference Call Participants

Jeff Cohen - Ladenburg Thalmann & Co.
Edward Marks - H.C. Wainwright
Bill Dezellem - Tieton Capital Management
Sean McGowan - ROTH MKM Partners
J.P. Mark - Farmhouse Equity Research

Operator

Thank you for standing by. My name is Mandeep, and I'll be your operator today. At this time, I'd like to welcome everyone to the ChromaDex Third Quarter 2024 Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. [Operator Instructions].

Thank you. I would now like to turn the call over to Ben Shamsian, Investor Relations. You may begin.

Ben Shamsian

Thank you. Good afternoon, and welcome to ChromaDex Corporation's third quarter of 2024 results investor call. With us today are ChromaDex's Chief Executive Officer, Rob Fried; Chief Financial Officer, Ozan Pamir; and Senior Vice President of Scientific and Regulatory Affairs, Dr. Andrew Shao. Dr. Shao will join the call for Q&A.

Today's conference call may include forward-looking statements including statements related to ChromaDex's research and development and clinical trial plans and the timing and results of such trials, the timing of future regulatory filings, the expansion of sales of Niagen products and ingredients in new markets, business development opportunities, future financial results, cash needs, operating performance, the investor interest, and business prospects and opportunities as well as anticipated results of operations.

Forward-looking statements represent only the company's estimates on the date of this conference call and are not intended to give any assurance as to the actual future results. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties.

Many factors could cause ChromaDex's actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These Risk Factors include those contained in ChromaDex's quarterly report on Form 10-Q most recently filed with the SEC, including results of operations, financial condition, cash flows, as well as global market and economic conditions on our business.

Please note that the company assumes no obligation to update any forward-looking statements after the date of this conference call to conform with the forward-looking statements, actual results or to changes in its expectations.